Ovarian Cancer: Not as Silent as You’ve Heard

Not exactly — it is better thought of as a "whispering" cancer. It does cause symptoms — persistent bloating, feeling full quickly, pelvic pain and urinary urgency — but they are subtle and easy to dismiss. Knowing them, and seeing a doctor when they are new, frequent and last most days for a few weeks, is the best way to catch it sooner.

The four symptoms that matter most are persistent bloating, feeling full quickly or difficulty eating, pelvic or lower-tummy pain, and needing to pass urine urgently or more often. Fatigue, a change in bowel habit and back pain can also occur. The pattern to act on is symptoms that are new, happen most days, and are frequent — especially if they last more than two to three weeks.

Almost always, no — occasional bloating is extremely common and usually harmless. What matters is bloating (or feeling full quickly, pelvic pain, or urinary urgency) that is new, happens most days, and does not settle over two to three weeks. That deserves a check — not to alarm you, but because catching ovarian cancer sooner makes a real difference.

Not a reliable one for women at average risk. CA-125 blood tests and ultrasound scans are not recommended as screening because they miss cancers and cause false alarms. The best protection is knowing the symptoms and knowing your family history, so that inherited (BRCA) risk can be identified and managed. Women at high inherited risk should discuss a personalised plan with a specialist.

It is worth discussing with a doctor. A family history of ovarian or breast cancer — especially at a young age or in several relatives — can point to an inherited gene change like BRCA1 or BRCA2. Genetic counselling and a test can clarify your risk, and if you carry it, there are proven ways to lower your chances. Everyone diagnosed with ovarian cancer is also offered genetic testing.

BRCA1 and BRCA2 are genes that normally help protect against cancer. An inherited change (mutation) in one of them raises the risk of both ovarian and breast cancer — which is why a family history of either matters. As many as 1 in 5 ovarian cancers are linked to an inherited gene change. Knowing your BRCA status can guide treatment and lets relatives take preventive action.

Most likely not. The great majority of ovarian cysts, especially before menopause, are benign and often disappear on their own. A scan, and sometimes a blood test, help tell reassuring cysts from ones that need follow-up. Your doctor will advise whether anything more is needed — a cyst is not the same as cancer.

Most ovarian cancers do not have a single identifiable cause. The strongest risk factors are increasing age and an inherited gene change (like BRCA) or a family history of ovarian or breast cancer. Endometriosis, never having been pregnant, and a late menopause also play a part. Some things lower risk, including having children, breastfeeding and the contraceptive pill. Having a risk factor does not mean you will get ovarian cancer.

Most ovarian cancers are "epithelial," and the commonest and most aggressive of these is high-grade serous carcinoma, which is often linked to BRCA. A separate group, germ cell tumours, mostly affect younger women and are usually highly treatable, even curable. Rarer sex cord-stromal tumours arise from the ovary’s hormone-producing tissue and are often found early.

Assessment usually starts with a pelvic ultrasound and a CA-125 blood test, followed by a CT scan to see how far the cancer has spread. The diagnosis is often confirmed at surgery, when tissue is examined under a microscope. Everyone diagnosed is offered genetic (BRCA) testing. Importantly, CA-125 and ultrasound are used for assessment, not as a screening test for healthy women.

CA-125 is a protein that can be raised in the blood in ovarian cancer. It is useful for assessing a suspicious finding and for monitoring treatment, but it is not a screening test — it can be normal in some cancers and raised by many harmless conditions such as endometriosis, fibroids or even menstruation. Your doctor interprets it alongside your scans and symptoms.

Ovarian cancer is staged I to IV. Stage I is confined to one or both ovaries or fallopian tubes; stage II has spread within the pelvis; stage III has spread to the abdominal lining or lymph nodes; and stage IV has spread to distant organs. Many ovarian cancers are found at stage III — and, because the cancer responds so well to chemotherapy, even advanced disease is often very treatable.

It can be, especially when found early — and even advanced ovarian cancer is very treatable, because it responds unusually well to chemotherapy. Most women reach remission after surgery and chemotherapy; it can return, but modern maintenance therapy (especially for BRCA-related cancer) increasingly keeps it away for longer. Germ cell tumours in younger women are often curable even when advanced.

Yes. Ovarian cancer is one of the cancers that responds most strongly to chemotherapy, so even advanced disease is often very treatable. Most women — even at stage III — reach remission after surgery and chemotherapy. If it comes back, it usually stays sensitive to further treatment, and maintenance therapy helps keep it away for longer. Advanced does not mean untreatable.

The two mainstays are surgery and chemotherapy, planned by a multidisciplinary team. Surgery ("debulking") aims to remove as much of the cancer as possible and is coordinated with specialist gynaecologic-oncology surgeons; chemotherapy is given afterwards, and sometimes before. Many women then have maintenance or targeted therapy to delay the cancer’s return — this works especially well in BRCA-related cancer. Radiation has a limited, mainly symptom-relieving role.

Debulking, or cytoreductive surgery, aims to remove as much of the visible cancer as possible — often including the ovaries, fallopian tubes and uterus. Removing more of the cancer generally improves how well chemotherapy works. At CION this surgery is coordinated with specialist gynaecologic-oncology surgeons, while medical oncology (chemotherapy and maintenance therapy) is provided in-house, so the whole pathway is planned together.

Maintenance therapy is treatment given after surgery and chemotherapy to delay the cancer coming back. Modern maintenance and targeted therapies have improved how long remission lasts, and some of them work especially well in cancers linked to a BRCA change — another reason genetic testing matters. Your oncologist advises whether maintenance therapy is right for your situation.

Cost varies widely with the stage and treatment plan, and surgery may be delivered and billed at specialist partner centres, so it is best given as an indicative range after assessment. Eligible treatment may be covered under Aarogyasri or PMJAY at empanelled centres, and our team helps with insurance and EMI. Use the cost estimator on this page for an indicative figure, then request a callback for an accurate estimate.

There is no guaranteed way to prevent ovarian cancer, but some factors lower the risk, including having children, breastfeeding and the contraceptive pill. For women with a known BRCA change or strong family history, options such as enhanced monitoring and risk-reducing surgery can substantially lower risk — which is why genetic counselling is so valuable. Knowing your family history is the most important first step.

It can, because surgery may remove the ovaries. For younger women, fertility-sparing options are sometimes possible, particularly with germ cell tumours — this is discussed before treatment where appropriate. Where surgery brings on menopause, symptoms and long-term wellbeing are actively supported. Ask your team about fertility and menopause early, so your plan takes your priorities into account.